Bangladesh Medical Research Council (BMRC) has approved a Covid-19 vaccine developed by a Chinese company for the Phase-3 trial in Bangladesh.
The trial will be conducted at seven hospitals, dedicated to treating Covid-19 patients, BMRC Director Dr. Mahmood-uz-Jahan told Dhaka Tribune on Sunday.
“The trial of a Chinese vaccine will be conducted under the supervision of the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b). The trial is expected to begin in August,” he said.
The vaccine will be applied to a total of 4,200 patients of the seven selected hospitals, he added.
The hospitals are Magda General Hospital, Two units (units 1 and 2) of Dhaka Medical College and Hospital (DMCH), Kurmitola General Hospital, Holy Family Red Crescent Medical College Hospital, Kuwait Bangladesh Friendship Government Hospital, and Mahanagar General Hospital.
However, the trial of other drugs for the treatment of Covid-19 patients has been going on in Bangladesh since March.
The icddr,b, and Institute of Epidemiology Disease Control And Research (IEDCR) are conducting the clinical trials after a team of physicians from Bangladesh Medical College (BMC), led by Prof Dr Tarek Alam, claimed that a combination of anti-parasitic drug ivermectin along with antibiotic doxycycline has yielded tremendous success in treating Covid-19 infection.